Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL.

Leukemia. 2009 Jul;23(7):1343-5. doi: 10.1038/leu.2009.59. Epub 2009 Mar 19. No abstract available.

2.

[TET2 gene in hematological diseases].

Li S, Wang XQ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Jun;22(3):836-41. doi: 10.7534/j.issn.1009-2137.2014.03.049. Review. Chinese.

PMID:
24989305
3.

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.

Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC, Xu M.

Blood. 2011 Oct 27;118(17):4509-18. doi: 10.1182/blood-2010-12-325241. Epub 2011 Jul 29.

4.

[TET2 as a gatekeeper for hematologic malignancies].

Muto H, Sakata-Yanagimoto M, Chiba S.

Rinsho Ketsueki. 2015 Jun;56(6):651-6. doi: 10.11406/rinketsu.56.651. Japanese.

PMID:
26256875
5.

FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.

de Oliveira FM, Miguel CE, Lucena-Araujo AR, de Lima AS, Falcão RP, Rego EM.

Med Oncol. 2013 Mar;30(1):483. doi: 10.1007/s12032-013-0483-1. Epub 2013 Feb 7.

PMID:
23389918
6.

ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.

Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, Kolb B, Durieu I, Gyan E, Livideanu C, Chèze S, Diouf M, Garidi R, Georgin-Lavialle S, Asnafi V, Lhermitte L, Lavigne C, Launay D, Arock M, Lortholary O, Dubreuil P, Hermine O.

PLoS One. 2014 Jan 21;9(1):e85362. doi: 10.1371/journal.pone.0085362. eCollection 2014.

7.

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL.

Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6.

8.

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR.

Blood. 2010 Apr 8;115(14):2891-900. doi: 10.1182/blood-2009-08-236596. Epub 2009 Dec 11.

9.

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.

Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP.

Blood. 2009 Jun 18;113(25):6403-10. doi: 10.1182/blood-2009-02-205690. Epub 2009 Apr 16.

10.

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.

Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A.

Nature. 2010 Dec 9;468(7325):839-43. doi: 10.1038/nature09586.

11.

Chromosomal abnormalities in transformed Ph-negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations.

Nguyen-Khac F, Lesty C, Eclache V, Couronné L, Kosmider O, Andrieux J, Collonge-Rame MA, Penther D, Lafage M, Bilhou-Nabera C, Chapiro E, Mozziconacci MJ, Mugneret F, Gachard N, Nadal N, Lippert E, Struski S, Dastugue N, Cabrol C, Bernard OA; Groupe Francophone de Cytogénétique Hématologique.

Genes Chromosomes Cancer. 2010 Oct;49(10):919-27. doi: 10.1002/gcc.20802.

PMID:
20629097
12.

TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.

Bacher U, Weissmann S, Kohlmann A, Schindela S, Alpermann T, Schnittger S, Kern W, Haferlach T, Haferlach C.

Br J Haematol. 2012 Jan;156(1):67-75. doi: 10.1111/j.1365-2141.2011.08911.x. Epub 2011 Oct 24.

PMID:
22017486
13.

FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions.

La Starza R, Crescenzi B, Nofrini V, Barba G, Matteucci C, Brandimarte L, Pierini V, Testoni N, Musto P, Paolini S, Gianfelici V, Storlazzi CT, Pierini A, Berchicci L, Gorello P, Mecucci C.

Leuk Res. 2012 Jan;36(1):37-41. doi: 10.1016/j.leukres.2011.08.004. Epub 2011 Sep 13.

PMID:
21920603
14.

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.

Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC.

Blood. 2010 Mar 11;115(10):2003-7. doi: 10.1182/blood-2009-09-245381. Epub 2010 Jan 8.

15.

[TET2 dysregulation in hematologic malignancies].

Sakata-Yanagimoto M.

Rinsho Ketsueki. 2014 Oct;55(10):1893-902. Review. Japanese. No abstract available.

PMID:
25297753
16.

Roles of IDH1/2 and TET2 mutations in myeloid disorders.

Inoue S, Lemonnier F, Mak TW.

Int J Hematol. 2016 Jun;103(6):627-33. doi: 10.1007/s12185-016-1973-7. Epub 2016 Mar 15. Review.

PMID:
26980223
17.

TET2 mutation in diffuse large B-cell lymphoma.

Kubuki Y, Yamaji T, Hidaka T, Kameda T, Shide K, Sekine M, Kamiunten A, Akizuki K, Shimoda H, Tahira Y, Nakamura K, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Kitanaka A, Shimoda K.

J Clin Exp Hematop. 2017;56(3):145-149. doi: 10.3960/jslrt.56.145.

18.

Dysregulation of TET2 in hematologic malignancies.

Chiba S.

Int J Hematol. 2017 Jan;105(1):17-22. doi: 10.1007/s12185-016-2122-z. Epub 2016 Nov 15. Review.

PMID:
27848178
19.

TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.

Jardin F, Ruminy P, Parmentier F, Troussard X, Vaida I, Stamatoullas A, Leprêtre S, Penther D, Duval AB, Picquenot JM, Courville P, Capiod JC, Tilly H, Bastard C, Marolleau JP.

Br J Haematol. 2011 May;153(3):413-6. doi: 10.1111/j.1365-2141.2010.08556.x. Epub 2011 Jan 31. No abstract available.

PMID:
21275969
20.

Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.

Scopim-Ribeiro R, Machado-Neto JA, Campos Pde M, Silva CA, Favaro P, Lorand-Metze I, Costa FF, Saad ST, Traina F.

Eur J Haematol. 2015 May;94(5):413-8. doi: 10.1111/ejh.12445. Epub 2014 Oct 1.

PMID:
25200248

Supplemental Content

Support Center